Esthesioneuroblastoma: A case with prolonged disease control

Andreia Coelho, Lúcia Águas, Lígia Osório, Paulo Linhares

Abstract


Esthesioneuroblastoma, a rare tumor arising from the olfactory vault, varies from being indolent to extremely aggressive. Owing to its rarity, the diagnosis, staging, and treatment of the disease are not well defined. According to a number of small observational retrospective studies and case reports, the disease’s actual treatment involves surgery, radiotherapy, and/or chemotherapy (either as a single treatment or used in combination), depending on the disease’s staging. Optimal treatment has not been standardized, particularly regarding the role of chemotherapy. We describe a case of advanced esthesioneuroblastoma with prolonged disease control, subjected to a multimodal therapy with surgery, radiotherapy, and chemotherapy, illustrating the benefits of this approach in managing a patient with esthesioneuroblastoma. Herein, we analyze the most important and controversial issues of this type of neoplasia.

Keywords


esthesioneuroblastoma; nasal cavity; surgery; radiotherapy; chemotherapy

Full Text:

PDF

References


Berger L, Luc R, Richard D. L’esthesioneuroepitheliome olfactif (French) [Olfactory neuroblastoma]. Bull Assoc Etude Cancer 1924; 13: 410–421.

Broich G, Pagliari A, Ottaviani F. Esthesioneuroblastoma: A general review of the cases published since the discovery of the tumour in 1924. Anticancer Res 1997; 17(4A): 2683–2706.

Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuro-blastoma: A meta-analysis and review. Lancet Oncol 2001; 2(11): 683–690. doi: 10.1016/S1470-2045(01)00558-7.

Kadish S, Goodman M, Wang CC. Olfactory neuroblas-toma—A clinical analysis of 17 cases. Cancer 1976; 37(3): 1571–1576. doi: 10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L.

Su SY, Bell D, Hanna EY. Esthesioneuroblastoma, neu-roendocrine carcinoma, and sinonasal undifferentiated carcinoma: Differentiation in diagnosis and treatment. Int Arch Otorhinolaryngol 2014; 18(Suppl 2): S149–S156. doi: 10.1055/s-0034-1390014.

Kumar M, Fallon RJ, Hill JS, Davis MM. Esthesioneuroblastoma in children. J Pediat Hematol Onc 2002; 24(6): 482–487. doi: 10.1097/00043426-200208000-00015.

Faragalla H, Weinreb I. Olfactory neuroblastoma: A review and update. Adv Anat Pathol 2009; 16(5): 322–331. doi: 10.1097/PAP.0b013e3181b544cf.

Ow TJ, Bell D, Kupferman ME, DeMonte F, Hanna EY. Esthesioneuroblastoma. Neurosurg Clin N Am 2013; 24(1): 51–65. doi: 10.1016/j.nec.2012.08.005.

Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthe-sioneuroblastoma: A population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg 2007; 133(3): 276–280. doi: 10.1001/archotol.133. 3.276.

Dulguerov P, Calcaterra T. Esthesioneuroblastoma: The UCLA experience 1970–1990. Laryngoscope 1992; 102(8): 843–849. doi: 10.1288/00005537-199208000-00001.

Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, et al. Esthesioneuroblastoma: The Princess Margaret Hospital experience. Head Neck 2008; 30(12): 1607– 1614. doi: 10.1002/hed.20920.

Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, et al. Esthesioneuroblastoma: Continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg 2006; 132(2): 134–138. doi: 10.1001/archotol. 132.2.134.

Hirose T, Scheithauer BW, Lopes MBS, Gerber HA, Al-termatt HJ, et al. Olfactory neuroblastoma. An immuno-histochemical, ultrastructural, and flow cytometric study. Cancer 1995; 76(1): 4–19. doi: 10.1002/1097-0142 (19950701)76:1<4::AID-CNCR2820760103>3.0.CO;2-E.

Pickuth D, Heywang-Köbrunner SH, Spielmann RP. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: An analysis of 22 cases. Clin Otolaryngol Allied Sci 1999; 24(5): 457–461. doi: 10.1046/j.1365-2273.1999.00295.x.

Derdeyn CP, Moran CJ, Wippold FJ 2nd, Chason DP, Koby MB, et al. MRI of esthesioneuroblastoma. J Comput Assist Tomogr 1994; 18(1): 16–21.

Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, et al. Esthesioneuroblastoma: Prognosis and management. Neurosurgery 1993; 32(5): 706–715. doi: 10.1097/00006 123-199305000-00002.

Eden BV, Debo RF, Larner JM, Kelly MD, Levine PA, et al. Esthesioneuroblastoma: Long term outcome and patterns of failure — the University of Virginia experience. Cancer 1994; 73(10): 2556–2562. doi: 10.1002/1097-0142(1994 0515)73:10<2556::AID-CNCR2820731017>3.0.CO;2-S.

Ingeholm P, Theilgaard SA, Buchwald C, Hansen HS, Francis D. Esthesioneuroblastoma: A Danish clinico-pathological study of 40 consecutive cases. APMIS 2002; 110(9): 639–645. doi: 10.1034/j.1600-0463.2002.1100907.x.

Dias FL, Sá GM, Lima RA, Kligerman J, Leôncio MP, et al. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg 2003; 129(11): 1186–1192. doi: 10.1001/archotol.129.11.1186.

Patel SG, Singh B, Stambuk HE, Carlson D, Bridger PG, et al. Craniofacial surgery for esthesioneuroblastoma: Report of an international collaborative study. J Neurol Surg B Skull Base 2012; 73(3): 208–220. doi: 10.1055/ s-0032-1311754.

Gruber G, Laedrach K, Baumert B, Caversaccio M, Raveh J, et al. Esthesioneuroblastoma: Irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys 2002; 54(2): 486–491. doi: 10.1016/S0360-3016(02) 02941-3.

Chao KS, Kaplan C, Simpson JR, Haughey B, Spector GJ, et al. Esthesioneuroblastoma: The impact of treatment modality. Head Neck 2001; 23(9): 749–757. doi: 10.1002/ hed.1107.

Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, et al. Outcome and prognostic factors in ol-factory neuroblastoma: A rare cancer network study. Int J Radiat Oncol Biol Phys 2010; 78(4): 992–997. doi: 10. 1016/j.ijrobp.2009.09.019.

Devaiah AK, Andreoli MT. Treatment of esthesioneuro-blastoma: A 16-year meta-analysis of 361 patients. Laryngoscope 2009; 119(7): 1412–1416. doi: 10.1002/lary.20280.

Nichols AC, Chan AW, Curry WT, Barker FG, Deschler DG, et al. Esthesioneuroblastoma: The Massachusetts Eye and Ear Infirmary and Massachusetts General Hospital experience with craniofacial resection, proton beam radiation, and chemotherapy. Skull Base 2008; 18(5): 327–337. doi: 10.1055/s-2008-1076098.

Diaz EM Jr, Johnigan RH III, Pero C, El-Naggar AK, Roberts DB, et al. Olfactory neuroblastoma: The 22-year experience at one comprehensive cancer center. Head Neck 2005; 27(2): 138–149. doi: 10.1002/hed.20127.

Ward PD, Heth JA, Thompson BG, Marentette LJ. Esthesioneuroblastoma: Results and outcomes of a single institution’s experience. Skull Base 2009; 19(2): 133–140. doi: 10.1055/s-0028-1096195.

Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: Past, present, and future? Laryngoscope 2003; 113(3): 502–507. doi: 10.1097/00005537-200303000-00020.

Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, et al. Esthesioneuroblastoma: A Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol 2003; 123(3): 433–439. doi: 10.1080/00016480310001295.

Levine PA, McLean WC, Cantrell RW. Esthesioneuroblastoma: The University of Virginia experience 1960– 1985. Laryngoscope 1986; 96(7): 742–746. doi: 10.1288/ 00005537-198607000-00008.

Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys 2009; 73(2): 424–432. doi: 10.1016/j.ijrobp.2008. 04.037.

Noh OK, Lee SW, Yoon SM, Kim SB, Kim SY, et al. Radiotherapy for esthesioneuroblastoma: Is elective nodal irradiation warranted in the multimodality treatment approach? Int J Radiat Oncol Biol Phys 2011; 79(2): 443– 449. doi: 10.1016/j.ijrobp.2009.10.067.

Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chem-otherapy, surgery, and combined proton-photon radio-therapy. Cancer 2002; 94(10): 2623–2624. doi: 10.1002/ cncr.10537.

Zappia JJ, Carroll WR, Wolf GT, Thornton AF, Ho L, et al. Olfactory neuroblastoma: The results of modern treatment approaches at the University of Michigan. Head Neck 1993; 15(3): 190–196. doi: 10.1002/hed.2880150303.

Argiris A, Dutra J, Tseke P, Haines K. Esthesioneuro-blastoma: The Northwestern University experience. Laryngoscope 2003; 113(1): 155–160. doi: 10.1097/00005537-200301000-00029.

Wade PM Jr, Smith RE, Johns ME. Response of esthesioneuroblastoma to chemotherapy. Report of five cases and review of the literature. Cancer 1984; 53(5): 1036– 1041. doi: 10.1002/1097-0142(19840301)53:5<1036::AID-CNCR2820530504>3.0.CO;2-3.

Resto VA, Eisele DW, Forastiere A, Zahurak M, Lee DJ, et al. Esthesioneuroblastoma: The Johns Hopkins experience. Head Neck 2000; 22(6): 550–558. doi: 10.1002/ 1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0.

Sheehan JM, Sheehan JP, Jane JA Sr, Polin RS. Chemo-therapy for esthesioneuroblastomas. Neurosurg Clin N Am 2000; 11(4): 693–701.

Kiyota N, Tahara M, Fujii S, Kawashima M, Ogino T, et al. Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: A retrospective analysis of 12 cases. Cancer 2008; 112(4): 885–891. doi: 10.1002/cncr.23246.

Turano S, Mastroianni C, Manfredi C, Biamonte R, Ceniti S, et al. Advanced adult esthesioneuroblastoma success-fully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. J Neurooncol 2010; 98(1): 131–135. doi: 10.1007/s11060-009-0052-9.




DOI: http://dx.doi.org/10.30564/amor.v2i5.83

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Andreia Coelho, Lúcia Águas, Lígia Osório, Paulo Linhares

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.